We address this question in the results part MACC1 expression: “ Due to the procedure of cutting and staining, some samples could not be used for the evaluation. Samples with insufficiently representative tumor tissue were also excluded from the evaluation. Cores with representative tumor material and evaluable staining were available in 266 of 360 samples (73.9%)…”. To avoid misunderstandings, we corrected the abstract to: 266 Samples of 360 AGE/S patients were analyzed for MACC1 expression.
It would be nice to know the selumetinib sensitivity of the two used cell lines.